Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Kostek O. Am J Clin Oncol 2020;43:905-906.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kostek O. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Am J Clin Oncol 2020;43:905-906.
PMID: 33492837